Molecular Partners AG Corporate Call Transcript
Good day, and welcome to the EMPATHY Part A Top Line Results Call. (Operator Instructions) As a reminder, this call may be recorded. I would now like to turn the call over to Seth Lewis, Senior Vice President, Investor Relations. You may begin.
Thank you, Michelle. Good morning. And welcome to this conference call to review the positive top line data from Part A of the EMPATHY study, a global trial of ensovibep, a DARPin antiviral therapeutic for COVID-19.
My name is Seth Lewis, Senior Vice President of Investor Relations at Molecular Partners. And I'm joined this morning by Patrick Amstutz, Chief Executive Officer; [Chief] Officer; Michael Stumpp; Chief Operating Officer; and Nicolas Leupin. (technical difficulty) opening remarks.
And before we begin today's call, I'd like to remind, I'm making certain forward-looking statements and that these may be subject to change (technical difficulty) a public filing. (inaudible) to this on replay, this call was recorded
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
